Eli Lilly, Boehringer Ingelheim Get Europe OK for Jardiance in Systolic Heart Failure
June 21 2021 - 6:15AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. and Boehringer Ingelheim on Monday said the
European Commission approved the expanded use of their diabetes
drug Jardiance as a treatment for adults with symptomatic chronic
heart failure with reduced ejection fraction, also known as
systolic heart failure.
The companies said the approval is based on results from a study
in which Jardiance showed a significant 25% reduction in the
combined relative risk versus placebo of cardiovascular death or
hospitalization due to heart failure, adding that the findings from
the primary endpoint were consistent in subgroups with or without
type 2 diabetes.
Indianapolis-based drug maker Eli Lilly and Boehringer
Ingelheim, a family-owned pharmaceutical company based in
Ingelheim, Germany, jointly market Jardiance as part of a 2011
alliance.
Jardiance was first approved in 2014 for the treatment of adults
with insufficiently controlled type 2 diabetes mellitus.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 21, 2021 06:13 ET (10:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Sep 2023 to Sep 2024